Сравнение
Cagrilintide vs. Maridebart Cafraglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
нет данных
Молекулярная масса
4253.7 g/mol
нет данных
Период полувыведения
168 h
нет данных
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYнет данных
Механизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
1
из них на людях
3
1
Зафиксированные эффекты
3
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Maridebart Cafraglutide?
- Cagrilintide is classified as "Метаболизм", while Maridebart Cafraglutide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Maridebart Cafraglutide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Maridebart Cafraglutide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Maridebart Cafraglutide — Не одобрено. США: Cagrilintide — Не одобрено, Maridebart Cafraglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.